The physiological disposition of phenylbutazone (butazolidin) in man and a method for its estimation in biological material.

PubWeight™: 3.60‹?› | Rank: Top 1%

🔗 View Article (PMID 13109696)

Published in J Pharmacol Exp Ther on November 01, 1953

Authors

J J BURNS, R K ROSE, T CHENKIN, A GOLDMAN, A SCHULERT, B B BRODIE

Articles citing this

Effect of age and sex on human drug metabolism. Br Med J (1971) 5.19

Genetic control of dicumarol levels in man. J Clin Invest (1968) 2.45

Studies in detoxication. 69. The metabolism of alkylbenzenes: n-propylbenzene and n-butylbenzene with further observations on ethylbenzene. Biochem J (1956) 1.84

Phenylbutazone and its derivatives with special reference to G.27202. Br Med J (1959) 1.77

Genetic control of phenylbutazone metabolism in man. Br Med J (1970) 1.58

Alteration of the response of platelets to surface stimuli by pyrazole compounds. J Exp Med (1967) 1.48

Prostaglandin production by macrophages and the effect of anti-inflammatory drugs. Br J Pharmacol (1978) 1.40

The biopharmaceutical properties of solid dosage forms. I. An evaluation of 23 brands of phenylbutazone tablets. Can Med Assoc J (1967) 1.40

MUTUAL SUPPRESSION OF THE URICOSURIC EFFECTS OF SULFINPYRAZONE AND SALICYLATE: A STUDY IN INTERACTIONS BETWEEN DRUGS. J Clin Invest (1963) 1.09

Action of nonsteroidal, anti-inflammatory drugs on human and rat peripheral leucocyte migration in vitro. Ann Rheum Dis (1977) 0.97

Changes in human drug metabolism after long-term exposure to hypnotics. Br Med J (1972) 0.95

Effect of a phenylbutazone analog (4-[phenylthioethyl]-1, 2-diphenyl 3, 5-pyrazolidinedione) on urate clearance and other discrete renal functions in gouty subjects; evaluation as uricosuric agent. J Clin Invest (1956) 0.93

Acetanilide oxidation in phenylbutazone-associated hypoplastic anaemia. Br Med J (1974) 0.92

A chronic dose-ranging study of the pharmacokinetics of phenylbutazone in rheumatoid arthritic patients. Br J Clin Pharmacol (1981) 0.91

Metabolic effect of phenylbutazone in gouty and non-gouty arthritis. Ann Rheum Dis (1954) 0.91

Plasma concentration of phenylbutazone and its therapeutic effect-studies in patients with rheumatoid arthritis. Br J Clin Pharmacol (1976) 0.90

Phenylbutazone: a clinico-pharmacological study in rheumatoid arthritis. Br J Clin Pharmacol (1975) 0.89

Drug displacement from protein binding: isolation of a redistributional drug interaction in vivo. Br J Pharmacol (1971) 0.87

Influence of allopurinol on drug metabolism in man. Br J Pharmacol (1973) 0.82

An appraisal of phenylbutazone suppositories. Br Med J (1959) 0.82

Displacement from protein binding of sulphormethoxine by phenylbutazone using in vivo dialysis in rats. Br J Pharmacol (1969) 0.82

The pharmacology of fenclozic acid (2-(4-chlorophenyl)-thiazol-4-ylacetic acid; I.C.I. 54,450; 'Myalex'); a new compound with anti-inflammatory, analgesic and antipyretic activityl. Br J Pharmacol (1969) 0.81

Factors influencing the inhibitory action of anti-inflammatory drugs on carrageenin induced oedema. Br J Pharmacol (1971) 0.81

In vitro effects of non-steroidal anti-inflammatory drugs on human polymorphonuclear cells and lymphocyte migration. Br J Pharmacol (1978) 0.80

Studies of the action of some anti-inflammatory drugs on complement mediated immune haemolysis. Br J Clin Pharmacol (1975) 0.80

Intrinsic mineralocorticoid agonist activity of some nonsteroidal anti-inflammatory drugs. A postulated mechanism for sodium retention. J Clin Invest (1976) 0.79

Induction of a deficiency of steroid delta 4-5 alpha-reductase activity in liver by a porphyrinogenic drug. J Clin Invest (1977) 0.79

Acute effect of antipyretic analgesics, alone or in combination with alcohol, on human psychomotor skills related to driving. Br J Clin Pharmacol (1974) 0.78

Genetic and environmental factors affecting host response to drugs and other chemical compounds in our environment. Environ Health Perspect (1977) 0.75

Biopharmaceutical properties of solid dosage forms. Can Med Assoc J (1967) 0.75

Nitrazepam (Mogadon) in blood serum and urine and librium in urine. J Clin Pathol (1968) 0.75

Pharmacokinetics of phenylbutazone and oxyphenabutazone in the pig. Can J Comp Med (1975) 0.75

Phenylbutazone and chromosomal damage. Ann Rheum Dis (1975) 0.75

Articles by these authors

A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity. J Biol Chem (1952) 18.27

The physiological disposition and metabolic fate of hydrocortisone in man. J Clin Invest (1955) 6.74

Ascorbic acid in aromatic hydroxylation. I. A model system for aromatic hydroxylation. J Biol Chem (1954) 5.08

Identification and assay of serotonin in brain. J Pharmacol Exp Ther (1956) 4.17

The gastric secretion of drugs: a pH partition hypothesis. J Pharmacol Exp Ther (1957) 3.99

A chemical method for the determination of free choline in plasma. J Biol Chem (1953) 3.57

Norepinephrine depletion as a possible mechanism of action of guanethidine (SU 5864), a new hypotensive agent. Proc Soc Exp Biol Med (1960) 3.26

On the mechanism of intestinal absorption of drugs. J Pharmacol Exp Ther (1959) 3.16

Some physico-chemical factors in drug action. J Pharm Pharmacol (1957) 3.13

The fate of antipyrine in man. J Pharmacol Exp Ther (1950) 3.05

Serotonin release as a possible mechanism of reserpine action. Science (1955) 3.03

The direct determination of phosphatidyl ethanolamine and phosphatidyl serine in plasma and red blood cells. J Biol Chem (1953) 2.98

Ascorbic acid in aromatic hydroxylation. II. Products formed by reaction of substrates with ascorbic acid, ferrous ion, and oxygen. J Biol Chem (1954) 2.78

INTERACTION OF GUANETHIDINE WITH ADRENERGIC NEURONS. J Pharmacol Exp Ther (1965) 2.77

A concept for a role of serotonin and norepinephrine as chemical mediators in the brain. Ann N Y Acad Sci (1957) 2.71

Absorption of drugs from the rat small intestine. J Pharmacol Exp Ther (1958) 2.62

The fate of aminopyrine (pyramidon) in man and methods for the estimation of aminopyrine and its metabolites in biological material. J Pharmacol Exp Ther (1950) 2.54

The oxidation of drugs by liver microsomes: on the role of TPNH and oxygen. J Pharmacol Exp Ther (1957) 2.46

The fate of pentobarbital in man and dog and a method for its estimation in biological material. J Pharmacol Exp Ther (1953) 2.38

Enzymatic metabolism of drugs and other foreign compounds. Annu Rev Biochem (1958) 2.36

Serotonin as a mediator of reserpine action in brain. J Pharmacol Exp Ther (1956) 2.26

A potent new uricosuric agent, the sulfoxide metabolite of the phenylbutazone analogue, G-25671. J Pharmacol Exp Ther (1957) 2.20

Detoxication of drugs and other foreign compounds by liver microsomes. Science (1955) 2.20

Estimation of intracellular water in man. Am J Physiol (1950) 2.14

Evidence that serotonin has a role in brain function. Science (1955) 2.13

Pharmacological consequences of the selective release of peripheral norepinephrine by syrosingopine (Su 3118). J Pharmacol Exp Ther (1960) 2.10

The fate of thiopental in man and a method for its estimation in biological material. J Pharmacol Exp Ther (1950) 2.10

Adaptive increases in drug-metabolizing enzymes induced by phenobarbital and other drugs. J Pharmacol Exp Ther (1960) 2.04

Interaction of reserpine, serotonin, and lysergic acid diethylamide in brain. Science (1955) 1.99

Absorption of drugs from the stomach. I. The rat. J Pharmacol Exp Ther (1957) 1.86

Absorption of drugs from the stomach. II. The human. J Pharmacol Exp Ther (1957) 1.85

Mechanism of the potentiating action of beta-diethylaminoethyl diphenylpropylacetate. J Pharmacol Exp Ther (1954) 1.78

Enzymatic dealkylation of aminopyrine (pyramidon) and other alkylamines. J Biol Chem (1955) 1.77

The metabolic fate of phenylbutazone (butazolidin) in man. J Pharmacol Exp Ther (1955) 1.76

Pneumoconiosis in the tungsten-carbide tool industry; report of three cases. AMA Arch Ind Hyg Occup Med (1953) 1.64

Biochemical and pharmacological studies of RO 1-9569 (tetrabenazine), a nonindole tranquilizing agent with reserpine-like effects. J Pharmacol Exp Ther (1959) 1.63

The physiological disposition and metabolic fate of cortisone in man. J Clin Invest (1957) 1.62

On the mechanism of drug potentiation by iproniazid (2-isopropyl-1-isonicotinyl hydrazine). J Pharmacol Exp Ther (1956) 1.61

Ascorbic acid synthesis in normal and drug-treated rats, studied with L-ascorbic-1-C14 acid. J Biol Chem (1954) 1.61

Physiological disposition and fate of chlorpromazine and a method for its estimation in biological material. J Pharmacol Exp Ther (1956) 1.59

The enzymatic metabolism of hexobarbital (evipal). J Pharmacol Exp Ther (1955) 1.56

DRUG INTERACTIONS IN MAN. I. LOWERING EFFECT OF PHENOBARBITAL ON PLASMA LEVELS OF BISHYDROXYCOUMARIN (DICUMAROL) AND DIPHENYLHYDANTOIN (DILANTIN). Clin Pharmacol Ther (1965) 1.55

Possible interrelationship between release of brain norepinephrine and serotonin by reserpine. Science (1957) 1.54

The synthesis of l-ascorbic acid by the albino rat. J Biol Chem (1950) 1.53

Total body water in man. Am J Physiol (1950) 1.50

Inhibitory effects of beta-diethylaminoethyl diphenylpropylacetate on a variety of drug metabolic pathways in vitro. J Pharmacol Exp Ther (1954) 1.49

The importance of dissociaton constant and lipid-solubility in influencing the passage of drugs into the cerebrospinal fluid. J Pharmacol Exp Ther (1960) 1.47

RECENT VIEWS ON MECHANISMS FOR LOWERING SYMPATHETIC TONE. Circulation (1963) 1.44

On the mechanism of antidepressant action of imipraminelike drugs. Ann N Y Acad Sci (1962) 1.42

The use of procaine amide in cardiac arrhythmias. Circulation (1951) 1.42

Biochemical and pharmacological effects of the monoamine oxidase inhibitors, iproniazid, 1-phenyl-2-hydrazinopropane (JB 516) and 1-phenyl-3-hydrazinobutane (JB 835). J Pharmacol Exp Ther (1960) 1.41

Benign tumors of the lungs with special reference to adenomatous bronchial tumors. Dis Chest (1950) 1.41

Pathways of drug metabolism. J Pharm Pharmacol (1956) 1.41

The mechanism of serotonin and catecholamine uptake by platelets. J Pharmacol Exp Ther (1959) 1.40

Role of brain serotonin in reserpine action. Ann N Y Acad Sci (1957) 1.40

Structural requirements for bretylium and guanethidine-like activity. Life Sci (1962) 1.39

Release of serotonin from blood platelets by reserpine in vitro. J Pharmacol Exp Ther (1957) 1.39

The enzymatic reduction of chloramphenicol, p-nitrobenzoic acid and other aromatic nitro compounds in mammals. J Pharmacol Exp Ther (1957) 1.38

Metabolism of drugs in subjects with Laennec's cirrhosis. Med Exp Int J Exp Med (1959) 1.38

Postoperative pain; its use in the comparative evaluation of analgesics. Surgery (1952) 1.38

AN EVALUATION OF AUTOMATIC SUTURE WITH UKL-60 AND UKL-40 DEVICES BY PULMONARY RESECTION. Dis Chest (1964) 1.37

Assay of serotonin and related metabolites, enzymes, and drugs. Methods Biochem Anal (1958) 1.37

Microanalytical procedures for fluorometric assay of brain DOPA-5HTP decarboxylase, norepinephrine and serotonin, and a detailed mapping of decarboxylase activity in brain. J Neurochem (1961) 1.35

The physiological disposition and biotransformation of dibenamine and a method for its estimation in biological tissues. J Pharmacol Exp Ther (1952) 1.35

The role of body fat in limiting the duration of action of thiopental. J Pharmacol Exp Ther (1952) 1.32

Reserpine and guanethidine action on peripheral stores of catecholamines. Life Sci (1962) 1.27

Stimulatory effect of foreign compounds on ascorbic acid biosynthesis and on drug-metabolizing enzymes. Nature (1959) 1.26

Missing step in guinea pigs required for the biosynthesis of L-ascorbic acid. Science (1956) 1.22

Observations on the antirheumatic and physiologic effects of phenylbutazone (butazolidin) and some comparisons with cortisone. Am J Med (1954) 1.22

Effects of reserpine and cold-exposure on pituitary-adrenocortical function in rats. J Pharmacol Exp Ther (1961) 1.21

Stimulatory effect of barbital on urinary excretion of L-ascorbic acid and nonconjugated D-glucuronic acid. J Biol Chem (1957) 1.20

Pulmonary manifestations of scleroderma. AMA Arch Intern Med (1953) 1.19

THE ACTIONS OF RESERPINE, GUANETHIDINE AND METARAMINOL ON CARDIAC CATECHOLAMINE STORES. Life Sci (1964) 1.18

Results of a clinical trial of G-28315, a sulfoxide analog of phenylbutazone, as a uricosuric agent in gouty subjects. Arthritis Rheum (1958) 1.18

Enzymatic reduction of prontosil and other azo dyes. J Pharmacol Exp Ther (1957) 1.17

The physiological disposition of dicumarol in man. J Pharmacol Exp Ther (1950) 1.17

Interaction of monoamine oxidase inhibitors with physiological and biochemical mechanisms in brain. Ann N Y Acad Sci (1959) 1.17

Role for ganglionic norepinephrine in sympathetic synaptic transmission. Science (1961) 1.15

Metabolism of ascorbic acid and related uronic acids, aldonic acids, and pentoses. Ann N Y Acad Sci (1961) 1.15

Interaction of drugs with norepinephrine in the brain. Pharmacol Rev (1959) 1.15

Cortisone therapy in Hamman-Rich syndrome; report of a case. Am Rev Tuberc (1957) 1.15

Quinoline and its transformation products found in urine. J Biol Chem (1950) 1.14

Interaction of serotonin and lysergic acid diethylamide (LSD) in the central nervous system. Experientia (1955) 1.14

Storage synthesis, and metabolism of monoamines in the developing brain. J Neurochem (1962) 1.14

On the mechanism of action of reserpine: effect of reserpine on capacity of tissues to bind serotonin. J Pharmacol Exp Ther (1957) 1.13

Metabolic interactions between L-ascorbic acid and drugs. Ann N Y Acad Sci (1961) 1.12

AN EPIDEMIC OF INFECTIOUS HEPATITIS IN A GENERAL HOSPITAL. PROBABLE TRANSMISSION BY CONTAMINATED ORANGE JUICE. JAMA (1963) 1.12

Inhibition of drug metabolic pathways by the potentiating agent, 2, 4-dichloro-6-phenyl-phenoxyethyl diethylamine. J Pharmacol Exp Ther (1955) 1.11

Meprobamate as adjuvant therapy in hypertension: a preliminary report. Am J Med Sci (1957) 1.10

Studies on the mechanism of ventricular activity. VI. The depolarization complex in pure subendocardial infarction; role of the subendocardial region in the normal electrocardiogram. Am J Med (1954) 1.10

Relationship between the lipid solubility of drugs and their oxidation by liver microsomes. Biochem Pharmacol (1959) 1.10

The metabolism of 1-C14-L-ascorbic acid in guinea pigs. J Biol Chem (1951) 1.10